TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
PR Newswire•28/09/2026•08:04 ET
1
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up PR Newswire
Updated clinical data reinforces evidence of antitumor activity in heavily pretreated patients with advanced solid tumors
Get started
Create a free account to read the full story and Whiz Insights.